ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on core technologies, including expansion of indications for the Grabody platform SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company...
Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026
LOS ANGELES, Dec. 26, 2025 /PRNewswire/ -- From January 6–9, 2026, visitors can experience Arspura's next-generation range hoods at LVCC - South Hall 1- Booth 30725, where the brand will demonstrate how cleaner kitchen air can make everyday cooking more comfortable and confidence-building—especially for households that are more sensitive to fumes, odors, and lingering particles. For air-quality-conscious users, including people...
Life-Space TrioBiotic Series Lands in Southeast Asia, Revolutionizing Gut Health with Triple-Action Formula
KUALA LUMPUR, Malaysia, Dec. 25, 2025 /PRNewswire/ -- A significant shift is underway in the regional health and wellness landscape as the innovative Life-Space TrioBiotic supplement series officially enters the Southeast Asian market. The launch introduces a cutting-edge "three-in-one" approach to gut health, combining prebiotics, probiotics, and postbiotics in a single daily dose. The world of health and wellness has been...
China’s First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent’s TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer. The TABOSUN® and TYVYT® combination therapy significantly improved pathological complete response (pCR) rates and enabled most patients to avoid the burden of postoperative adjuvant chemotherapy. This therapy...
Life-space’s Patented Strain LPB27 Featured in Nature Supplement, Highlighting World-Class R&D Strength
KUALA LUMPUR, Malaysia, Dec. 25, 2025 /PRNewswire/ -- The Nature supplement highlights research exploring the potential of LPB27 and Bifidobacterium breve 207-1 in supporting digestive and metabolic health. Both strains have already been successfully integrated into multiple Life-space products and are highly favored by consumers globally. The inclusion of Life-space's proprietary strains in a Nature publication underscores the brand's robust...
Caliway’s Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies
Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management (CBL-0201WR Phase 2). The study will evaluate CBL-514 in combination with Zepbound® (Eli Lilly) in subjects with obesity or overweight. Efficacy endpoints...
Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an abstract on the Co-PSMA (NCT06907641) Investigator-Initiated Trial (IIT), led by Prof Louise...
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study
SHANGHAI, Dec. 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) for its self-developed anti-ST2 monoclonal antibody (R&D code: 9MW1911) to initiate a Phase IIa clinical study in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). As...
HKSH Medical Group Signed Memorandum of Understanding with Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen To Advance Precision Proton Therapy, Furthering the Healthy China Initiative
HONG KONG, Dec. 24, 2025 /PRNewswire/ -- In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group ("HKSH") and Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen ("Shenzhen Cancer Hospital") signed a memorandum of understanding ("MOU") on 11 December 2025. The MOU was signed by Dr. Walton LI, Chief...
Hakka Medicine Goes Global: Jiaying Pharmaceutical Launches the Global Promotion Plan for Hakka Medicine in Hong Kong
HONG KONG, Dec. 24, 2025 /PRNewswire/ -- Recently, Guangdong Jiaying Pharmaceutical Co., Ltd. held the "First Hakka Medicine Historical and Cultural Symposium" and the "Jiaying Hakka Medicine - Double-ingredient Throat Wind Relief Powder Product Promotion Conference" in Hong Kong SAR. Centered on the theme of "Bringing Hakka Medicine to Global Hakka People," the conference brought together authoritative experts in traditional...
